TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05092490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined serratus anterior plane block and transversus thoracis plane block
Description: The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard local infiltration technique
Description: Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
Study: NCT05230797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Oxide-Eugenol Cement
Description: Antimicrobial and antiseptic
Study: NCT04877418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TeleCIMT
Description: Mode applied remotely, through the principles and components of the CIMT protocol.
Study: NCT06415435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Microneedling
Description: Sylfirm X radiofrequency microneedling device
Study: NCT04993677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Given by IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
Study: NCT05050162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given high-dose cisplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given high-dose cisplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given low-dose cisplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given low-dose cisplatin IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06487182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: reiki

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo reiki
Description: placebo reiki
Study: NCT06397313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
Study: NCT04039204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Oral contraceptive prescribed by physician.
Study: NCT06346782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Parent-Child Interaction Therapy
Description: I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Parent-Child Interaction Therapy
Description: I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
Study: NCT05019573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black tea
Description: Black tea twice a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tea twice a day for 4 weeks
Study: NCT05764954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T System
Description: The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
Study: NCT06553404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoslow
Description: The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision
Description: Single vision glasses
Study: NCT06158321

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: M1 or DLPFC sham stimulation
Description: Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 rTMS
Description: The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLPFC rTMS
Description: The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
Study: NCT05815069

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-NOTA-pentixather PET/CT
Description: The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
Study: NCT05795491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Emitting Diode Therapy
Description: Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
Study: NCT05435352

Intervention type: PROCEDURE
Intervention: Core needle biopsy
Description: An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.

Intervention type: PROCEDURE
Intervention: Core needle biopsy
Description: An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
Study: NCT05320419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane preparation and injection (AM group)
Description: The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy (PT group)
Description: Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
Study: NCT06110598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
Study: NCT05820490

Intervention type: OTHER
Intervention: Whole Room Calorimeter
Description: The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.

Intervention type: OTHER
Intervention: Whole Room Calorimeter
Description: The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.

Intervention type: OTHER
Intervention: Mixed-Meal Tolerance Test (MMTT)
Description: The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.

Intervention type: OTHER
Intervention: Mixed-Meal Tolerance Test (MMTT)
Description: The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.

Intervention type: OTHER
Intervention: Core Body Temperature
Description: Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.

Intervention type: OTHER
Intervention: Core Body Temperature
Description: Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.

Intervention type: OTHER
Intervention: Morningness-Eveningness Questionnaire
Description: Participants will fill out a questionnaire that asks about your preference for morning or evening.

Intervention type: OTHER
Intervention: Morningness-Eveningness Questionnaire
Description: Participants will fill out a questionnaire that asks about your preference for morning or evening.

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.

Intervention type: OTHER
Intervention: Serial Blood Sampling
Description: Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.

Intervention type: OTHER
Intervention: Serial Blood Sampling
Description: Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
Study: NCT04411758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
Study: NCT04955613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyMove/VR system
Description: The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
Study: NCT06488430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention package for preventing cognitive decline
Description: Participants with mild cognitive impairment will be identified and they will participate in a pilot study for one-month duration. During pilot study they will be subjected to a multidomain intervention including nutritional advice, physical activity, cognitive stimulation training, social support and engagement and management of vascular risk factors.
Study: NCT06045221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT04744506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Marker Clip
Description: Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticle Suspension Injection
Description: Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticle Suspension Injection
Description: Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
Study: NCT06593834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacillus coagulans combined with the best treatment options for preventing aGVHD
Description: BAT means the best treatment options for preventing aGVHD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT
Study: NCT06609291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology
Description: The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
Study: NCT06612216

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.

Intervention type: OTHER
Intervention: No intervention was carried out
Description: This study observed differences in microbiota among different groups and therefore did not involve intervention.
Study: NCT06611826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
Description: The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
Study: NCT06612905

Intervention type: OTHER
Intervention: Detection of the time spent on social media
Description: The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).

Intervention type: OTHER
Intervention: Detection of the time spent on social media
Description: The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).

Intervention type: OTHER
Intervention: Evaluation of body composition and basal metabolic rate
Description: They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)

Intervention type: OTHER
Intervention: Evaluation of body composition and basal metabolic rate
Description: They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)

Intervention type: OTHER
Intervention: Evaluation of eating behavior among social media users
Description: Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.

Intervention type: OTHER
Intervention: Evaluation of eating behavior among social media users
Description: Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
Study: NCT06612983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Treatment
Description: Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.